The $6.5 million jury verdict in Takeda Pharmaceuticals' first Actos trial didn't last long. Judge Kenneth Freeman tossed out the jury's judgment, saying that plaintiffs' lawyers didn't prove that Jack Cooper's bladder cancer was linked to his use of Actos.
The jury in the latest Fosamax trial has spoken, and it spoke for Merck. In a federal court in New Jersey, the panel determined that plaintiff Bernadette Glynn's broken leg wasn't caused by the bone drug Fosamax. It was the first jury verdict among the more than 3,000 lawsuits claiming Fosamax caused serious femur fractures.
An unapproved, foreign version of the cosmetic treatment Botox has shown up in the U.S., this time in counterfeit packaging that makes it appear to be the same product that is made for the U.S. market.
For more than a year, U.S. authorities have been tightening a noose around Internet pharmacy company Canada Drugs, which reportedly was the source of counterfeit Avastin shipped last year to doctors.
Japan's Takeda has gotten into more local hot water over the recall earlier this year of a lot of its Alinamin-F5 dietary supplement sold in Japan for vitamin B1 deficiency.
A safety watchdog group has analyzed the FDA's adverse event data on the entire GLP-1 class of diabetes drugs, finding more reports of pancreatitis and pancreatic cancer for these drugs compared with older treatments.
For months FDA regulators have been wrestling with the dangers of allowing a flood of cheap, generic version of the highly addictive OxyContin on the market vs. consumers with pain issues having access to cheaper meds.
A new study says doctors in the Southern part of the U.S. are too often prescribing drugs for elderly patients that can have severe side effects and for which there are better alternatives.
Citing heart risks, an EMA committee has recommended further restrictions for Protelos, an osteoporosis drug made by Servier, the company at the center of a scandal in France for off-label use of its Mediator diabetes drug, which also was tied to heart risks.
Once Avandia's heart risks were fully understood, the former blockbuster from GlaxoSmithKline, was tightly restricted in the U.S. and pulled from the European market. The diabetes drug was at the heart of the company's $3 billion settlement with federal authorities last year. Now, the FDA will take another hard look at the research on its side effects to see if there is something more the agency should do to limit its use.